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Despite decades of research, wound complications remain a major cause of postoperative mortal-
ity, especially in the face of multiple comorbidities. Addressing the issue of anastomotic leakages
and impaired wound healing from a new angle is of great interest with the prospect of having direct
impact on patient outcome. Recently, aqueous suspensions of silica and iron oxide nanoparticles
have been employed to connect biological tissue by serving as an adhesive layer eventually lead-
ing to macroscopic gluing of tissue. In this work, we explore the prospects of this effect by intro-
ducing bioactive tissue adhesives composed of nanoparticles produced via scalable and sterile
flame spray pyrolysis. We investigate six different metal oxides on cytocompatibility, hemostatic
activity and adhesive properties in a small intestine lap joint model. While bioglass nanoparticles
show exceptionally strong procoagulant and adhesive properties, the cell membrane integrity is
impaired at high particle concentrations. Interestingly, when bioglass is combined with ceria, a
material that has well-documented cytoprotective effects, the resulting hybrid particles exhibit the
same beneficiary effects as bioglass while featuring superior cytocompatibility. Taken together,
we demonstrate highly modular synthesis of nanoparticles expressing adhesive properties in con-
junction with tailored bioactivity. Such bioactive nanoparticles as adhesion nuclei in wound healing
have a wide range of potential applications in surgical wound care and regenerative medicine.
1 Introduction
Haemorrhage has been found to be the main cause of death
within the first 24 hours of a traumatic injury1. Emergency
medical services and surgeons are challenged by poorly healing
wounds as well as by bleedings that are difficult to staunch2. The
impeded barrier function of wounded tissue is also responsible
for a comparatively high rate of post-operative complications in
surgical patients. Iatrogenic injuries, anastomatic leakages and
infections after resections3 or abdominal surgery4,5 pose inextri-
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cable problems to surgeons.
Conventional anastomotic techniques such as suturing, stapling
or taping are often insufficient for the management of abdominal
wounds and anastomoses, especially on the long term. Recent
studies have found that around 10 % of patients who undergo
colorectal surgery suffer from subsequent anastomotic leakages4.
Such leakages have a notoriously high morbidity (around 20 %)
which illustrates how important a new wound management solu-
tion is. Furthermore, conventional anastomotic techniques do not
offer active promotion of the healing process6. In recent years, a
plethora of novel wound management solutions have addressed
the shortcomings of conventional techniques. A range of bioma-
terials has been developed to figure as hemostats, adhesives, and
sealants, especially for post-operative wound treatment7,8. Nat-
ural materials used for these purposes, such as fibrin glues, have
documented compatibility issues and lead to allergic reactions
in some patients9. Synthetic surgical materials are more read-
ily available, yet less adhesive and effective than their natural
counterparts10.
Nanotechnology has given rise to a whole new tool set for the
design of clinical biomaterials. Rose et al. 11 have shown that
aqueous suspensions of silica nanoparticles glue biological tissue
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together by a mere physical phenomenon: The particles form an
adhesive layer due to the adsorption of proteins onto their sur-
face. The resulting bridging layer can sustain high amounts of
stress due to protein rearrangement processes on the particle sur-
face. While advantages compared to current wound closing tech-
niques have been shown by Meddahi-Pellé et al. 12, the particles
were solely tested on their adhesive properties, neglecting pos-
sible bioactivity and compatibility. Additionally, large quantities
of high-quality nanoparticles are required in order to provide suf-
ficient surface area for protein binding, posing a synthetic chal-
lenge to nanoparticle manufacturing. Nevertheless, the reported
adhesive properties of nanoparticle suspensions are very promis-
ing and serve as a base for exciting research; a multitude of ma-
terials, architectures and applications are left to explore.
Here, we develop bioactive metal oxide nanoparticle-based tis-
sue adhesives for wound management applications. We employ
highly scalable liquid-feed flame spray pyrolysis (LF-FSP) to pro-
duce different metal oxide nanoparticles with comparable size
and surface area from low cost chemical precursor solutions at
full stoichiometric control. This one-step combustion process13
allows the reproducible synthesis of high quality14 metal oxide
nanoparticles on an industrial scale up to kg/h15–18 without the
formation of harmful byproducts and in absence of endotoxins.
Furthermore, the freedom of choice in materials and the process
modularity enables the design of oxide particles featuring com-
plex architectures including hermetic coatings19,20, Janus-shaped
hybrid particles21,22, and a variety of primary particle shapes23.
In order to have a meaningful set of nanoparticles, we selected
silica and iron oxide particles for their documented ability to glue
soft tissue12 and bioactive metal oxide particles (45S5 bioglass,
13-93B3 borate glass, and ceria) for their beneficial effects in soft
tissue healing24. We systematically investigate these metal ox-
ide particles on their suitability as tissue glues by first assessing
their hemostatic and cytotoxic activities. We then demonstrate
their ability to glue biological tissue in a small intestine model
and benchmark the particles against commercial alternatives. Fi-
nally, we present the development of a hybrid particle that unifies
the benefits of different materials.
2 Materials and methods
2.1 Particle synthesis
All non-commercially available particles were produced by liquid-
feed flame spray pyrolysis (LF-FSP)13. 5 mL/min of appropri-
ate precursor solutions was fed to a water-cooled spray nozzle,
dispersed by 5 L/min O2 with a pressure drop of approximately
1.5 bar at the nozzle tip. The spray was ignited by a premixed
CH4 / O2 (1.5 L/min / 3.2 L/min) flame. Particles were collected
on a glass fiber filter mounted above the flame.
The precursors were dissolved in equal parts of 2-ethylhexanoic
acid and acetonitrile such that the total metal ion concentration
of the solution was 0.3 mol/L. The precursor composition of the
particles is as follows: SiO2 (100 wt% HMDSO), Fe2O3 (100 wt%
Iron(III) acetylacetonate), CeO2 (100 wt% Cerium(III) nitrate),
bioglass (41 wt% calcium 2-ethylhexanoate, 38 wt% sodium 2-
ethylhexanoate, 3 wt% tributyl phosphate, 18 wt% HMDSO), bo-
rate glass (65 wt% tributyl borate, 16 wt% calcium acetylaceto-
nate, 6 wt% sodium 2-ethylhexanoate, 1 wt% tributyl phosphate,
5 wt% magnesium acetylacetonate, 7 wt% potassium acetylacet-
onate).
Hybrid bioglass/ceria particles were produced by a modified
FSP setup, similar to the one described previously by Starsich
et al. 25. Ceria precursor solution (0.3 mol/L, composition as
above) was fed to a water-cooled spray nozzle at a rate of
6 mL/min. It was dispersed by 5 mL/min O2 with a pressure drop
of approximately 1.5 bar at the nozzle tip. The spray was ignited
by a premixed CH4 / O2 (1.25 L/min / 2.5 L/min) flamelet. The
entire flame was enclosed in a stainless steel tube and sheathed
with O2 (20 L/min) and pressurized air (100 L/min). The bioglass
precursor solution (0.2 mol/L, composition as above) was fed at
3 mL/min through a tube opening 11 cm downstream of the FSP
nozzle and dispersed with 13 L/min of N2 into the FSP plume
26.
Particles were collected on a glass fibre filter mounted above the
flame.
2.2 Particle Characterization
For all experiments, the produced nanoparticles were dispersed
without addition of stabilizers. Aqueous suspensions of metal ox-
ide particles are comparatively stable for hours27 (see also ESI,
Figure S1).
2.2.1 Transmission electron micrographs
Nanoparticles were suspended in 0.5 mL deionized water and a
drop of 10µL was placed on a clean parafilm surface. A grid with
a formvar film (Electron Microscopy Science, Lucerna-Chem AG,
Lucerne, Switzerland) was placed on top of the drop for 10 min.
Any excess liquid was removed and the grid air-dried. After dry-
ing, the grid was imaged in a JEOL 2000FX transmission electron
microscope (TEM).
2.2.2 Elemental analysis
Elemental analysis by inductively coupled plasma atomic emis-
sion spectroscopy (ICP-OES) was conducted by Bachema AG,
Rütistrasse 22, CH-8952 Schlieren.
2.2.3 XRD measurements
X-ray diffraction patterns (XRD) were obtained with a Bruker D8
advance diffractometer (40 kV, 40 mA, CuKα radiation) at 2θ =
10°-70°.
2.2.4 Brunauer-Emmett-Teller absorption
The particle specific surface area (SSA) was measured by N2
adsorption at 77 K using a five-point Brunauer-Emmet-Teller
method (Tristar, Micromeritics) after degassing the samples for
1 h at 150 °C in N2.
The density ρ and the specific surface area SSA was used to esti-
mate the primary particle diameter dBET using Equation 128.
dBET [nm] =
6000
SSA[m2/g] ·ρ[g/cm3] (1)
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2.2.5 Hydrodynamic diameter determination by dynamic
light scattering
Particle suspensions of 0.13 mg/mL in ethanol were probe-
sonicated for 5 minutes to break possible agglomerates. Three
dynamic light scattering (DLS) measurements per sample were
conducted using a Zetasizer (Nano ZS90, Malvern Instruments).
In between measurements, the suspensions were vortex-mixed to
ensure homogeneity. The hydrodynamic diameter dDLS and poly-
dispersity index (PDI) found for particle suspensions in distilled
water can be found in Table S1 of the ESI.
2.2.6 Zeta potential measurements
Particle suspensions of 0.05 mg/mL in ultrapure water were son-
icated in an ultrasonic bath for 5 min. Zeta potential measure-
ments with automated pH adjustment were performed with a
Zetasizer (Nano ZS, Malvern Instruments). Borate glass proved
to be unstable in water, which rendered zeta potential measure-
ments unreliable.
2.3 Assessment of hemostatic properties
The hemostatic properties of the produced nanoparticles were in-
vestigated based on the tiered framework for assessing nanoparti-
cle biocompatibility developed by the National Cancer Institute’s
Nanotechnology Characterization Laboratory (NCI-NCL)29. For
comparison, the commercially available Aerosil 380 fumed silica
particles (Sigma-Aldrich) were included in the set of particles.
The nanoparticles were suspended in PBS according to their spe-
cific surface area such that the total particle surface was the same
for all suspensions and equivalent to a silica nanoparticle concen-
tration of 10 mg/mL (dry weight). Additionally 10-fold and 100-
fold dilutions were created. All suspensions were vortex-mixed
and left in an ultrasonic bath for 20 min. To effectively remove
particles from cellular suspensions before absorbance measure-
ments in order to prevent interference, the suspensions were cen-
trifuged at 6000 x g for 5 min as illustrated on Figures S5(a) and
S5(b).
A one-way ANOVA followed by a Bonferroni post-hoc test was
performed to find statistical significance between metal oxide
suspension performance in the hemolysis and cytotoxicity assays
(GraphPad Prism version 6.00 for Windows, GraphPad Software,
La Jolla California USA, www.graphpad.com).
2.3.1 Hemolysis
After obtaining written informed consent, whole blood from
healthy volunteers was collected in tubes containing 0.109 mol/L
citrate as an anti-coagulant and centrifuged at 800 x g. The
plasma was collected for the coagulation measurements. The re-
maining red blood cells were resuspended in PBS and washed
three times. The hemoglobin concentration was adjusted to
30 mg/mL. A 1 % Triton X solution was used as positive and PBS
as negative control. 180µL red blood cells and 20µL of nanopar-
ticle suspension were added to each well of a 96-well plate. After
incubation for 3 h at 37 ◦C, the contents of the wells were ex-
tracted and centrifuged at 6000 x g for 5 min. 100µL of each
supernatant was transferred to a well on a 96-well flat-bottom
plate. Subsequently, the absorption at 570 nm (hemoglobin) was
measured with a Mithras2 LB 943 multimode microplate reader.
2.3.2 Cytotoxicity
Monocytes (THP-1, human monocytic cell line) were cultured in
RPMI-1640 supplemented with 10 % fetal bovine serum (FBS).
For experiments, THP-1 cells were suspended in medium with
1 % FBS at a cell concentration of 5×105 cells/mL. 180µL of the
THP-1 suspension and 20µL nanoparticle suspension were added
to each well of a 96-well plate. After overnight incubation at
37 ◦C, the contents of the wells were extracted and centrifuged
at 6000 x g for 5 min. 50µL of each supernatant was added
to a well on a 96-well plate and combined with 50µL of Cyto-
Tox 96 reagent (CytoTox 96 Non-Radioactive Cytotoxicity Assay,
Promega, Madison, WI USA). After 30 min incubation at room
temperature, the absorption at 490 nm was measured with a plate
reader (Mithras2 LB 943).
2.3.3 Coagulation
20µL of nanoparticle suspension were added to tubes containing
180µL blood plasma each. After 30 min incubation at 37 ◦C, the
contents of the wells were extracted and centrifuged at 6000 x
g) for 5 min. 100µL of each supernatant was transferred to a
well on a 96-well flat-bottom plate and recalcified with 65µL of
50 mM CaCl2 solution. Subsequently, fibrin polymerization was
evaluated by measuring absorption at 405 nm in 50 s intervals
during 1 h with a plate reader (Mithras2 LB 943)30. The clot-
ting time is a measure for how long it takes a coagulation process
to reach saturation. To evaluate this, the maximum absorbance
of the wells containing plasma treated with Aerosil 380 was de-
termined. The clotting time was defined as the moment a well
reached an absorbance within 5 % of that value.
2.4 Adhesion on small intestine
Small intestine from pig (obtained from Schlachtbetrieb St.
Gallen AG, Bazenheid, Switzerland) was stretched and cut to
pieces of 2.5 cm width and 15 cm length with a scalpel. As a ref-
erence, Ludox TM-50 (Sigma-Aldrich), a commercially available
aqueous suspension of silica nanoparticles, was included in the
particle set. The pieces were cut in the middle and glued serosa
to serosa by spreading 20µL of 10 wt% nanoparticle suspension
between them. The overlap joint was 1 cm long and was pressed
together for 1 min with a 2 kg weight. Subsequently, slips of pa-
per were applied onto both ends of the glued piece to prevent
sliding during the measurement. Tensile tests were performed on
a Zwick Z100 machine at a pulling rate of 15 mm/s. The intes-
tine was immersed in PBS until use and processed without any
pre-treatment such as drying. During each measurement, the in-
testine was exposed to air during 10 min. To benchmark the parti-
cles against an existing solution, the fibrin sealant patch TachoSil
(Baxter) was applied. TachoSil was pre-moistened in PBS and
then used to bridge the two intestine pieces with the active (yel-
low) side. In a second adhesion measurement illustrated in Fig-
ure 5(d), the pieces were cut to 3.5 cm width and 12 cm length.
SPSS (IBM SPSS, Chicago, IL, USA) was used for statistical
analyses. Linear regression analysis was performed to assess the
influence of metal oxide suspensions (independent variables) on
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adhesion forces (dependent variable).
3 Results and discussion
3.1 Physicochemical characterization
LF-FSP allows the production of metal oxide particles with uni-
form size distribution (typically 20 to 200nm primary particle
size). Here, we produced five different metal oxide nanopow-
ders and recorded transmission electron micrographs (TEM) of
them. Figure 1(a) shows mostly spherical primary particles with
comparable diameters below 100 nm. The CeO2 particles feature
smaller primary particle sizes than the other metal oxides. The
borate glass particles exhibit networking between each other due
to their reactivity in aqueous environments31.
The X-ray diffraction patterns in Figure 1(b) show that borate
glass, bioglass, and SiO2 are mostly amorphous with partial crys-
talline phases, while ceria and iron oxide are primarily crystalline.
In agreement with Strobel and Pratsinis 32, maghemite (γ-Fe2O3)
is the predominant crystalline phase when iron oxide is produced
in an open flame setting. The TEM images and XRD patterns of
the bioglass nanoparticles are in good agreement with the original
report on flame-made bioglass by Brunner et al. 33. Also the other
produced metal oxide nanoparticles show morphologies and crys-
tallinities comparable to previous reports on iron oxide19, borate
glass34, silica35, and ceria13.
According to elemental analysis by ICP-OES, the produced bio-
glass nanoparticles are composed of 53 % SiO2, 4 % P2O5, 18 %
CaO and 25 % Na2O. These ratios are in agreement with the
theoretical composition of 45S5 bioglass (45 % SiO2, 6 % P2O5,
24.5 % CaO and 24.5 % Na2O).
The specific surface areas (SSA) of as-prepared nanoparticles
determined by the Brunauer-Emmett-Teller (BET) method are
shown in Table 1. All particles feature comparable specific surface
areas ranging from 60 m2/g to 227 m2/g, with SiO2 nanoparti-
cles exhibiting the biggest SSA. The SSA equivalent average pri-
mary particle diameters (dBET ) displayed in Table 1 are in good
agreement with the TEM images. Dynamic light scattering (DLS)
measurements further show that all particles have comparable
hydrodynamic diameters. Hydrodynamic size results shown here
were determined in ethanol since DLS measurements of bioglass
in water (see ESI, Table S1) showed high variation. In summary,
the similarity in size, surface area and shape allows the compar-
ison of the produced particles with respect to other properties,
such as hemostatic and adhesive activities, both being critical for
wound healing applications.
Table 1 BET and DLS analysis results. Mean values ± SD are reported.
Nanoparticle SSA [m2/g] dBET [nm] dDLS [nm] PDI
SiO2 227 ± 3 10 176 ± 4 0.18
Fe2O3 59.6 ± 0.2 19.2 165.3 ± 0.2 0.35
CeO2 84.5 ± 0.6 9.3 399 ± 4 0.31
Bioglass 110 ± 1 20 229 ± 4 0.23
Borate glass 68.1 ± 0.3 33.8 210 ± 10 0.35
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Fig. 1 (a) Transmission electron micrographs of all produced metal ox-
ide nanoparticles show comparable primary particle sizes. (b) X-ray
diffraction patterns (XRD) of all as-prepared metal oxide nanoparticles
reveal that silica, bioglass and borate glass are mostly aomrphous, while
maghemite and ceria are rather crystalline.
3.2 Hemostatic activity of flame made-metal oxide nanopar-
ticles
When injury occurs, bleeding needs to be halted promptly to pre-
vent excessive blood loss that otherwise could have detrimen-
tal consequences. To assess if and by how much the nanopar-
ticles increase the coagulation rate, fibrin polymerization was
measured over time in a plasma coagulation assay. For compari-
son, commercially available fumed silica nanoparticles with well-
documented hemolytic36 and procoagulant30 activity (Aerosil)
were included in the experiments. The native properties of
the particles, especially surface charge, are pivotal on how pro-
teins adsorb in biological environments. In turn, protein adsorp-
tion and protein corona formation are key processes that govern
hemostatic and adhesive properties of the nanoparticle suspen-
sions37. Since protein adsorption prior to particle application will
mask potential differences between different metal oxide parti-
cles38, we characterized and applied native particle suspensions.
All particles except borate glass showed a significant increase in
blood clotting speed as shown in Figure 2(a). Bioglass showed ex-
traordinary procoagulant properties and saturation was reached
substantially faster than other metal oxides particles. More specif-
ically, saturation in plasma clotting was reached three times faster
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Fig. 2 (a) Coagulation increase compared to PBS over time. Bioglass
reaches saturation significantly faster than any other particle. n=3 in-
dependent samples per particle type, measured at a silica nanoparticle
concentration of 0.1 mg/mL and surface-equivalent amounts of the five
other particles. (b) Zeta potential of the particles at different pH values.
All potentials are negative at physiological pH. n=3 measurements per
pH. The mean values and SD are displayed. The coagulation speeds
coincide with the negativity of the zeta potential at physiological pH.
in samples exposed to bioglass compared to other nanoparticles
with well-documented procoagulant properties such as Aerosil.
As can be seen in Figure 2(b), the zeta potential at ph 7 is most
negative for bioglass followed by silica, iron oxide and ceria. The
order coincides with the respective coagulation speeds. This cor-
relation is in agreement with Ostomel et al. 39 who showed that
more negatively charged metal oxides triggered blood coagula-
tion faster and accelerated the process more than neutral or pos-
itively charged particles. The reason for this is most likely the
increased contact activation of coagulation factors at the particle-
plasma interface which leads to higher clotting speeds40.
3.3 Adhesion on soft tissue
Apart from coagulation, hemostasis can be reached by mechan-
ically closing a wound. To be applicable for tissue gluing, the
nanoparticles need to exhibit strong adhesive properties. Adhe-
sion is not only necessary for gluing, but also to keep the particles
localized on a wounded site. Some of the most promising poten-
tial uses of such nanoparticle-based tissue adhesives are topical
applications to organs with heavy blood flow, such as parenchy-
mal injuries of abdominal organs, and sealing of leakages of in-
testinal fluids. Since intestinal anastomotic leakages are among
the most dreaded complications after abdominal surgery, the use
of particle-based adhesives on intestine is of particular clinical
relevance4,41.
To quantify the adhesion on soft tissue, particle suspensions
were spread between pieces of small intestine, as illustrated in
Figure 3(a). Tensile force measurements on the glued pieces,
shown in Figure 3(b), allowed quantification of the adhesive
properties. After spreading the particles, the glued pieces were
easily handleable and stable. The forces the pieces were able
to withstand while being pulled apart vertically were measured
and plotted as a function of the pulling distance. As an exam-
ple, the force curves for bioglass are shown in Figure 3(c). Their
shape indicates a rupture event at the peak of each curve, where
the measured force had been building up until the piece ripped
at the glued site. A comparison of all metal oxide particle sus-
pensions is found in Figure 3(d). All particle suspensions exhib-
ited measurable adhesion above 100 mN. Bioglass significantly
improved adhesion (β=0.679, R2=0.461, p=0.015) while other
metal oxides had no significant influence. The bioglass-treated
pieces were able to withstand forces of around 200 mN, which
can be attributed to the well-documented strong tissue-bonding
properties of bioglass24.
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Fig. 3 (a) The nanoparticles were spread on pieces of small intestine to
glue them together. (b) The maximum tensile stress they could withstand
was measured in a lap joint experiment. (c) Normalized force-distance
curves for the lap joints glued with bioglass. The shape of the curves is
typical for a rupture event. (d) Maximum tensile force values for all par-
ticles displayed in boxplots (whiskers show the minimum and maximum
value). The gluing properties of bioglass surpass those of all other tested
particles. n=3 independent samples per particle type.
3.4 Cytocompatibility
In addition to strong hemostatic and adhesive properties, it is piv-
otal that nanoparticle-based tissue glues are innocuous to cells.
There is a high demand of oxygen in the microenvironment sur-
rounding a wound due to the increased oxygen consumption by
metabolically active cells. A deficiency of oxygen supply results
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in impaired wound healing, which makes it especially important
that applied nanoparticles do not harm erythrocytes42. Similar-
ily, the cells involved in the inflammatory cascade are of cru-
cial importance in the early stages of the wound healing process.
Monocytes and macrophages play a big role in regulating the im-
mune response to foreign bodies, cleaning the wound from debris
and preventing infections43. It has been shown that the toxicity
of metal oxide particles is cell-type dependent and that surface
charge and particle morphology govern cellular toxicity44. There-
fore, dose-dependent effects on the integrity of both human ery-
throcytes and monocytes were measured for the different metal
oxide particles.
The hemolytic activity of the nanoparticles was assessed by
incubation with human erythrocytes and measurement of freed
hemoglobin. Similarly, the release of lactate dehydrogenase
(LDH) was measured after 24 hours exposure of human mono-
cytes to metal oxide nanoparticles. LDH is released into me-
dia from damaged cells and is a sensitive marker for cellular
damage45. As displayed in Figure 4, both cytolysis experiments
demonstrate the substantially high lytic activity of silica nanopar-
ticles, even at concentrations as low as 0.01 mg/mL ( 50 %
relative to full lysis by Triton X). This is in line with previous
reports on the highly hemolytic activity of various silica nanopar-
ticles attributing their toxicity to particle characteristics including
geometry, porosity and surface charge46. This finding also con-
firms that the application of highly concentrated silica nanopar-
ticle suspensions poses issues concerning toxicity and biodegrad-
ability47–50. Interestingly, surface-equivalent amounts of bioglass
are less lytic and only show significant lysis at concentrations of
1 mg/mL. These results confirm earlier reports by Macˇkovic´ et al.
demonstrating high cytocompatibility of flame-made bioglass for
concentrations of at least 200µg/mL51. The fact that ceria par-
ticles show lower lysis than the PBS negative control and the
amount of lysed cells decreases at increased concentration may
be explained by their well-documented antioxidant properties52.
A similar negative dose response has been observed for iron ox-
ide nanoparticles. While the effect is present very consistently in
both cytolysis assays and cannot be easily explained, trypan blue
showed comparable viability for all iron oxide concentrations in-
vestigated (see Figure S5). Overall, a good correlation between
hemolysis and monocyte viability was found for all particles on
a similar dosage basis. Interestingly, the differences in zeta po-
tential only partially account for the different cytolytic activities
of the different metal oxide nanoparticles. While the zeta poten-
tial of silica and bioglass nanoparticles at neutral pH is compara-
ble, silica is significantly more cytolytic. This corroborates earlier
findings that cytolytic activity is governed not solely by surface
charge, but also other factors, such as morphology and shape44.
Iron oxide and ceria on the other hand show comparable and less
negative zeta potential values, and lower cytolysis than silica and
bioglass.
3.5 Bioglass/ceria hybrid nanoparticle
In summary, it is evident that rapid treatment of a wound with
bioglass nanoparticles could critically promote hemostasis and tis-
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Fig. 4 (a) Hemolytic and (b) cytotoxic activity of the particles relative
to Triton X (100 % lysis). All silica-containing particles show dose-
dependent cell lysis. Ceria and iron oxide stabilize the cells. n=3 in-
dependent samples per particle type, measured at silica nanoparticle
concentrations of 0.01 mg/mL, 0.1 mg/mL and 1 mg/mL, and surface-
equivalent amounts of the other particles. The mean values and SD are
displayed.
sue adhesion. Even though silica nanoparticles also show signifi-
cantly increased coagulation, their inferior cytocompatibility47,50
makes them unsuited for direct application to a wound. When
applied at high concentrations, however, bioglass also exhibits
potentially unfavorable cytolytic activities as seen in Figure 4. In
contrast, ceria nanoparticles have shown beneficial effects on cell
viability but very weak procoagulant and adhesive properties as
indicated in Figure 2(a) and Figure 3. We therefore sought to
unify both properties, i.e. high biocompatibility and strong ad-
hesion, in a hybdrid particle. By feeding more than one type of
precursor to a flame spray reactor, hybrid nanoparticles can be
produced with full stoichiometric control. To test the hypothe-
sis that a hybrid particle could unite procoagulant, adhesive and
cell-stabilizing properties, a bioglass/ceria nanoparticle (85 wt%
CeO2, 15 wt% bioglass) was produced by LF-FSP. Characteriza-
tion of three different batches of said hybrid particles confirms
good reproducibility of the synthesis process. Transmission elec-
tron micrographs and energy-dispersive X-ray spectra show that
the hybrid particles consist of larger ceria crystallites (up to 50
nm) surrounded by fine bioglass particles (ESI, Figure S2). X-ray
diffractograms (ESI, Figure S3) show characteristic ceria peaks
masking the signal of the amorphous bioglass. The hydrodynamic
diameter of the hybrid (440 ± 20 nm, PDI = 0.46) is compara-
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ble to bioglass and ceria particles (see Table 1). Figure 5 offers
a comparison of the hybrid particle to the single components.
Figure 5(a) and Figure 5(b) show that the lytic effect of bio-
glass/ceria nanoparticles is significantly lower than bioglass only,
both on human erythrocytes (0.1 mg/mL: p < 0.05) and mono-
cytes (1 mg/mL: p < 0.001). This demonstrates that the addition
of ceria in the nanoparticle has indeed reduced the lytic effect ex-
hibited by bioglass, especially at concentrations of 1 mg/mL. The
cytocompatibility experiments show that the bioglass character of
the hybrid particles is relatively high, given that they only contain
a small amount of bioglass. This can be explained by the fact that
the hybrid particles consist of small bioglass particles located on
the ceria surface. Thus there is a comparatively large bioglass sur-
face area exposed despite its low content. Figure 5(c) indicates
that the clotting time of the hybrid particles is comparable to that
of bioglass and significantly shorter than those of other metal ox-
ide particles. This again falls in line with the surface charge of
the hybrid particles (ESI, Figure S4) which is close to bioglass, lo-
cated between the zeta potential of pure ceria and bioglass. The
short clotting time also confirms that the bioactivity of the hybrid
is heavily influenced by the bioglass part.
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Fig. 5 (a,b) The hemolytic and cytotoxic activity of the hybrid particles at
high concentrations was significantly lower compared to bioglass. (c) The
hybrid particles show similar procoagulant properties as bioglass, outpe-
forming all other particles. n=3 independent samples per particle type.
The mean values and SD are displayed. (d) Tensile force measurements
show highly adhesive properties for the hybrid particle, surpassing those
of other particles and TachoSil. n=3 samples per particle type. Whiskers
show the minimum and maximum value.
In order to better understand how the measured adhesion of
the metal oxide nanoparticle formulations compares to alterna-
tives, we benchmarked the bioglass/ceria nanoglue against Lu-
dox, iron oxide and TachoSil. Ludox is a commercially avail-
able silica nanoparticle dispersion and has shown strong adhesive
properties11. Similarily, iron oxide nanoparticles have demon-
strated strong adhesion to skin and liver tissue12. TachoSil is a
fibrin sealant patch that is widely used to close and seal blood
vessels after surgery53 and has been praised for its high adhesive
strength on soft tissue54. The tensile force measurement results
are displayed in Figure 5(d). Comparison with the adhesion ex-
periment displayed in Figure 3 shows similar forces for iron ox-
ide treated tissue, despite different widths of the overlap joints
(2.5 vs 3.5 cm). This can be explained by the fact that the tissue
gluing properties of the nanoparticle suspensions not containing
bioglass are comparatively low in this setting and therefore dif-
ferences in force are not easily detectable between different sizes
of glued areas. The hybrid particles significantly improved tissue
adhesion (β=0.873, R2=0.762, p<0.001). No significant influ-
ence was found for iron oxide particle suspensions, Ludox 10%
and TachoSil.
Taken together, the hybrid particles exhibit extraordinary prop-
erties and successfully consolidate the advantages of bioglass and
ceria. The addition of small quantities of bioglass to a nanoparti-
cle results in strong adhesive and procoagulant properties. While
showing the same increase in coagulation speed and strong ad-
hesive properties as pure bioglass, the hybrid particles are less
harmful to human erythrocytes and monocytes. These results
demonstrate that particle characteristics can be tuned selectively
by adequate changes to the synthesis conditions, such as precur-
sor composition and reactor settings. This freedom allows tai-
loring particle properties to fit the need of certain prospective
applications, such as treating postsurgical abdominal injuries.
With regard to clinical translation of metal oxide based
nanoglues, compatibility and degradability take center stage. Nu-
merous in vivo and in vitro studies have shown that both ce-
ria55,56 and bioglass51,57 nanoparticles are well tolerated. Fur-
thermore, they exhibit biologically relevant activities that make
them suitable for a range of medical applications. Bioglass pro-
motes the growth of new tissue and features strong adhesion
to soft tissue24. It has been used in the clinics for more than
three decades58, mostly to repair or replace damaged parts of the
musculo-skeletal system59. In recent years, the potential of bio-
glass for soft tissue repair has become evident and several studies
have reported compelling results concerning wound healing and
the promotion of angiogenesis using bioglass-based fillers24,60,61.
Since ceria figures as a reactive oxygen species (ROS) scavenger,
it exhibits several exciting properties which include improved
wound healing62–64, anti-inflammatory52 and anti-fibrotic65 ac-
tivity, and angiogenetic properties66. Our results show that merg-
ing the benefits of these two clinically relevant materials is possi-
ble and in view of their additional bioactive properties, they offer
great prospects for comprehensive wound healing solutions.
4 Conclusions
In this work we produced several metal oxide nanoparticles by
flame spray pyrolysis and investigated their hemostatic and adhe-
sive properties. The bioactive ceramic bioglass promotes coagu-
lation to a great extent and features remarkable adhesive proper-
ties, outperforming other metal oxide nanoparticles such as silica,
iron oxide or ceria in both fields. We demonstrated that a bio-
glass/ceria hybrid nanoparticle exhibits the same procoagulant
and adhesive properties as bioglass while being significantly less
cytolytic. These results illustrate that particle properties can be
Journal Name, [year], [vol.], 1–9 | 7
devised by choosing the appropriate materials and that more so-
phisticated particles could exhibit even more exciting properties.
Due to its versatility, there are many potential medical applica-
tions of this nanoparticle based approach. While there are various
solutions on the market, this non-invasive and effective method is
a complement to existing ones. Before clinical application, more
investigation on biocompatibility is necessary.
The nanoglue developed here unifies gluing properties with
bioactivity in a relatively simple formulation of constituents with
well-documented biological compatibility. Introducing bioactive
nanoparticles as adhesion nuclei enables engineering the mi-
croenvironment of a wound in support of the natural repair pro-
cess. Importantly, recent progress in tissue engineering stipulates
novel solutions for attaching scaffolds to biological tissues in a
minimally invasive way that promotes integration. Hence the de-
veloped nanoglue could, in addition to all the obvious applica-
tions, find uses well beyond classical wound healing.
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